All other patients were considered low risk (n = 6). Overall, 22 patients (42%) had failed at least one previous autologous or allogeneic HCT. Median patient age was 48 years (range, 6-65 years), and median donor age was 35 years (range, 19-58 years). The study protocol was ...
In many cases, this condition is due to a mutation in theJAK2gene. Because of it often being hereditary, first-degree relatives have a 5 to 7-fold higher risk of developing the disease in comparison to the general population [19]. There is no definite cure for this condition. It is, h...
proportional hazards models considering year of MDS diagnosis as a possible 1.0 Untreated 0.9 Lenalidomide-treated 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0123456 Patients at risk, n Time from diagnosis (years) Untreated 125 Lenalidomide-treated 79 53 58 39 24 18 9 97 119 128 120 98 Figure 2....
Lenalidomide is an immunomodulatory agent recently reported to be effective in the treatment of transfusion-dependent anemia due to low- or intermediate-1 risk myelodysplastic syndromes (MDS) associated with a deletion 5q (del 5q) cytogenetic abnormality. We conducted a multicenter, single-arm clinica...
With an overall life expectancy of around 80 years, there is a small margin of profit in terms of overall survival in the low-risk MDS population. Therefore, health-related quality of life (HRQoL) is a primary treatment goal of installed treatments. The acknowledgment of HRQoL as a treatment...